Table 2.
Rate of incident cancers in patients with prior malignancy*
| DMARD (n = 117) | All anti-TNF (n = 177) | |
|---|---|---|
| Person-years of followup | 235 | 515 |
| Person-years of followup per patient, median (IQR) | 1.9 (1.3–2.7) | 3.1 (2.0–3.9) |
| Incident malignancies, no. | 9 | 13 |
| Patients with incident malignancies, no. | 9 | 11 |
| Rate of incident malignancy/1,000 person-years (95% CI) | 38.3 (17.5–72.7) | 25.3 (13.4–43.2) |
| IRR (95% CI) | Referent | 0.56 (0.23–1.35) |
| IRR adjusted for age and sex (95% CI) | Referent | 0.58 (0.23–1.43) |
| Propensity-adjusted IRR (95% CI) | Referent | 0.45 (0.09–2.17) |
*
DMARD = disease-modifying antirheumatic drug; anti-TNF = anti–tumor necrosis factor; IQR = interquartile range; 95% CI = 95% confidence interval; IRR = incidence rate ratio.